Cargando…

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

OBJECTIVE: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Pomati, Giulia, Cirillo, Alessio, Mammone, Giulia, Ciurluini, Fabio, Cerbelli, Bruna, Sciattella, Paolo, Ralli, Massimo, Romeo, Umberto, De Felice, Francesca, Catalano, Carlo, Vullo, Francesco, Della Monaca, Marco, Amirhassankhani, Sasan, Tomao, Silverio, Valentini, Valentino, De Vincentiis, Marco, Tombolini, Vincenzo, Della Rocca, Carlo, Polimeni, Antonella, di Gioia, Cira, Corsi, Alessandro, D’Amati, Giulia, Mezi, Silvia, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274020/
https://www.ncbi.nlm.nih.gov/pubmed/34253248
http://dx.doi.org/10.1186/s12967-021-02975-3
_version_ 1783721486161281024
author Botticelli, Andrea
Pomati, Giulia
Cirillo, Alessio
Mammone, Giulia
Ciurluini, Fabio
Cerbelli, Bruna
Sciattella, Paolo
Ralli, Massimo
Romeo, Umberto
De Felice, Francesca
Catalano, Carlo
Vullo, Francesco
Della Monaca, Marco
Amirhassankhani, Sasan
Tomao, Silverio
Valentini, Valentino
De Vincentiis, Marco
Tombolini, Vincenzo
Della Rocca, Carlo
Polimeni, Antonella
di Gioia, Cira
Corsi, Alessandro
D’Amati, Giulia
Mezi, Silvia
Marchetti, Paolo
author_facet Botticelli, Andrea
Pomati, Giulia
Cirillo, Alessio
Mammone, Giulia
Ciurluini, Fabio
Cerbelli, Bruna
Sciattella, Paolo
Ralli, Massimo
Romeo, Umberto
De Felice, Francesca
Catalano, Carlo
Vullo, Francesco
Della Monaca, Marco
Amirhassankhani, Sasan
Tomao, Silverio
Valentini, Valentino
De Vincentiis, Marco
Tombolini, Vincenzo
Della Rocca, Carlo
Polimeni, Antonella
di Gioia, Cira
Corsi, Alessandro
D’Amati, Giulia
Mezi, Silvia
Marchetti, Paolo
author_sort Botticelli, Andrea
collection PubMed
description OBJECTIVE: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach. METHODS: A total of 124 patients with locally incurable R/M HNSCC receiving weekly (21) or three-weekly (103) chemotherapy plus cetuximab in a first line setting from December 2010 to September 2020 were retrospectively reviewed. Treatment outcomes in terms of objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities were analysed. RESULTS: Patients in the three-week subgroup were ECOG PS 0 (39) and 1 (64) while patients in weekly group (21) were all PS 2. No significant differences were reported in terms of age, sex, smoking and previous alcohol abuse considering the two distinct subgroups. Moreover, no statistically significant difference was found in PFS and OS between the two treatment subgroups. The response rate was 35% (36 patients) and 34% (7 patients) in three-week and weekly treatment group, respectively. Seventy patients (68%) in the three-week group experienced chemotherapy-related toxicities, predominantly G3. In the weekly group a predominantly low-grade toxicity was found in a lower number of patients (52%). CONCLUSION: The weekly schedule appears to be an active and safe strategy in frail patients with R/M HNSCC. Based on these data, a weekly schedule could be considered as a first line treatment in all frail patients excluded from pembrolizumab treatment and a study on the combination of weekly chemotherapy and immunotherapy should be performed.
format Online
Article
Text
id pubmed-8274020
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82740202021-07-13 Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era Botticelli, Andrea Pomati, Giulia Cirillo, Alessio Mammone, Giulia Ciurluini, Fabio Cerbelli, Bruna Sciattella, Paolo Ralli, Massimo Romeo, Umberto De Felice, Francesca Catalano, Carlo Vullo, Francesco Della Monaca, Marco Amirhassankhani, Sasan Tomao, Silverio Valentini, Valentino De Vincentiis, Marco Tombolini, Vincenzo Della Rocca, Carlo Polimeni, Antonella di Gioia, Cira Corsi, Alessandro D’Amati, Giulia Mezi, Silvia Marchetti, Paolo J Transl Med Research OBJECTIVE: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach. METHODS: A total of 124 patients with locally incurable R/M HNSCC receiving weekly (21) or three-weekly (103) chemotherapy plus cetuximab in a first line setting from December 2010 to September 2020 were retrospectively reviewed. Treatment outcomes in terms of objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities were analysed. RESULTS: Patients in the three-week subgroup were ECOG PS 0 (39) and 1 (64) while patients in weekly group (21) were all PS 2. No significant differences were reported in terms of age, sex, smoking and previous alcohol abuse considering the two distinct subgroups. Moreover, no statistically significant difference was found in PFS and OS between the two treatment subgroups. The response rate was 35% (36 patients) and 34% (7 patients) in three-week and weekly treatment group, respectively. Seventy patients (68%) in the three-week group experienced chemotherapy-related toxicities, predominantly G3. In the weekly group a predominantly low-grade toxicity was found in a lower number of patients (52%). CONCLUSION: The weekly schedule appears to be an active and safe strategy in frail patients with R/M HNSCC. Based on these data, a weekly schedule could be considered as a first line treatment in all frail patients excluded from pembrolizumab treatment and a study on the combination of weekly chemotherapy and immunotherapy should be performed. BioMed Central 2021-07-12 /pmc/articles/PMC8274020/ /pubmed/34253248 http://dx.doi.org/10.1186/s12967-021-02975-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Botticelli, Andrea
Pomati, Giulia
Cirillo, Alessio
Mammone, Giulia
Ciurluini, Fabio
Cerbelli, Bruna
Sciattella, Paolo
Ralli, Massimo
Romeo, Umberto
De Felice, Francesca
Catalano, Carlo
Vullo, Francesco
Della Monaca, Marco
Amirhassankhani, Sasan
Tomao, Silverio
Valentini, Valentino
De Vincentiis, Marco
Tombolini, Vincenzo
Della Rocca, Carlo
Polimeni, Antonella
di Gioia, Cira
Corsi, Alessandro
D’Amati, Giulia
Mezi, Silvia
Marchetti, Paolo
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
title Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
title_full Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
title_fullStr Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
title_full_unstemmed Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
title_short Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
title_sort weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274020/
https://www.ncbi.nlm.nih.gov/pubmed/34253248
http://dx.doi.org/10.1186/s12967-021-02975-3
work_keys_str_mv AT botticelliandrea weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT pomatigiulia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT cirilloalessio weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT mammonegiulia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT ciurluinifabio weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT cerbellibruna weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT sciattellapaolo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT rallimassimo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT romeoumberto weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT defelicefrancesca weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT catalanocarlo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT vullofrancesco weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT dellamonacamarco weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT amirhassankhanisasan weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT tomaosilverio weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT valentinivalentino weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT devincentiismarco weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT tombolinivincenzo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT dellaroccacarlo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT polimeniantonella weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT digioiacira weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT corsialessandro weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT damatigiulia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT mezisilvia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera
AT marchettipaolo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera